Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBT (2023 - 2025)

Monte Rosa Therapeutics' EBT history spans 3 years, with the latest figure at -$46.1 million for Q4 2025.

  • For Q4 2025, EBT fell 170.86% year-over-year to -$46.1 million; the TTM value through Dec 2025 reached -$39.7 million, down 91.82%, while the annual FY2025 figure was -$39.7 million, 91.82% down from the prior year.
  • EBT reached -$46.1 million in Q4 2025 per GLUE's latest filing, down from -$30.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $65.0 million in Q4 2024 to a low of -$46.1 million in Q4 2025.
  • Average EBT over 3 years is -$16.3 million, with a median of -$31.1 million recorded in 2024.
  • Peak YoY movement for EBT: soared 295.42% in 2024, then tumbled 170.86% in 2025.
  • A 3-year view of EBT shows it stood at -$33.3 million in 2023, then skyrocketed by 295.42% to $65.0 million in 2024, then crashed by 170.86% to -$46.1 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's EBT are -$46.1 million (Q4 2025), -$30.3 million (Q3 2025), and -$11.1 million (Q2 2025).